Pr. Francois Spertini is an expert in vaccine clinical development and trained in Internal Medicine as well as Clinical Immunology and in Allergology in Lausanne, then in Experimental Immunology at the Department of Pathology of the University Medical Center in Geneva and in the Children’s Hospital, at Harvard Medical School, Boston. He joined the Division of Allergy and Immunology at CHUV, Lausanne in 1992 where he is currently Chief Physician and in charge of training clinical Fellows in his field of expertise. His experimental interests are focused on immunologic mechanisms of tolerance in allergy and asthma in humans, as well as in the development of novel vaccine strategies in the field of malaria, hepatitis C, tuberculosis and allergy. François Spertini is Vice President of the specialist board of SSAI. He was president of the society from 2001-2003.
Vaxeal’s highly experienced executive team has an extensive track record in company management, immunotherapy product development and regulatory compliance. The Board also brings a wealth of diverse corporate and M&A experience.
Vaxeal’s pre-eminent Scientific Advisory Board advises the company in the fields of immunology, immunotherapy, clinical immuno-oncology, infectious diseases and regulatory affairs.